Aenova, Galvita Finalize Strategic Partnership

Published on: 

Goal of the deal is to boost the production of oral dosage forms.

The Aenova Group, contract development and manufacturing organization (CDMO) and Galvita have entered into a strategic partnership. The aim of the partnership is to improve the development, formulation and production of oral dosage forms.


With this purpose in mind, Galvita's patented templated-inverted particles (TIP) technology consists of clinically tested calcium-phosphate microcapsules that can be loaded with various active ingredients via a self-loading mechanism. The capsules are then processed into tablets, which have the property of disintegrating almost instantly upon ingestion, releasing the active ingredient. Aenova will offer this technology for customer projects at its site in Sisseln, Switzerland.

"The portfolio and the experience and knowledge of the individual companies complement each other perfectly in order to be able to offer an almost unique added value even faster for our customers and, above all, for patients worldwide,” note Jan Kengelbach, CEO of Aenova Group and Dr. Roland Haag, co-founder and CEO of Galvita.